You are here

GSK

Anatomy of a long-delayed biotech buyout: With its stock price beaten down, abandoned by potential bidders, Tesaro wound up in GSK’s eager arms

Anatomy of a long-delayed biotech buyout: With its stock price beaten down, abandoned by potential bidders, Tesaro wound up in GSK’s eager arms

Endpoints

Flag link:

Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

Biopharma Dive

ViiV Healthcare

Flag link:

GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'

GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'

Fierce Pharma

Flag link:

Should You Be Worried About the Return of Big Pharma Deals?

Should You Be Worried About the Return of Big Pharma Deals?

Motley Fool

Flag link:

GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca

GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca

Xconomy

PARP inhibitors

Flag link:

Crown Laboratories buys select OTC consumer healthcare brands from GSK

Crown Laboratories buys select OTC consumer healthcare brands from GSK

Pharmaceutical Business Review

Crown Laboratories

Flag link:

GlaxoSmithKline weighs plan to develop vaccine against fast-spreading gonorrhea: report

GlaxoSmithKline weighs plan to develop vaccine against fast-spreading gonorrhea: report

Fierce Pharma

Flag link:

A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries

A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries

BioSpace

developing countries

Flag link:

GSK seeks pediatric indication for Nucala in severe eosinophilic asthma

GSK seeks pediatric indication for Nucala in severe eosinophilic asthma

Pharmaceutical Business Review

eosinophilic asthma

Flag link:

7 drugs that raised eyebrows in Q3

7 drugs that raised eyebrows in Q3

Biopharma Dive

Clovis Oncology

Flag link:

GSK pancreatic cancer drug heads to phase 1 combo with Merck's Keytruda after positive mouse trial

GSK pancreatic cancer drug heads to phase 1 combo with Merck's Keytruda after positive mouse trial

Fierce Biotech

pancreatic cancer

Flag link:

GSK’s systemic STING agonist could overcome delivery hurdles

GSK’s systemic STING agonist could overcome delivery hurdles

BioCentury

Flag link:

Excellent quarter for GlaxoSmithKline

Excellent quarter for GlaxoSmithKline

GoinPharma

Flag link:

GSK tosses a trio of clinical-stage drugs on trial failures, winnowing out its respiratory pipeline as cancer moves to center stage

GSK tosses a trio of clinical-stage drugs on trial failures, winnowing out its respiratory pipeline as cancer moves to center stage

Endpoints

drug development

clinical trials

Flag link:

Long-lasting HIV injection is a step closer after second GSK study

Long-lasting HIV injection is a step closer after second GSK study

Reuters

Flag link:

GlaxoSmithKline expands API production for COPD inhalers as Advair sales wither

GlaxoSmithKline expands API production for COPD inhalers as Advair sales wither

Fierce Pharma

Flag link:

GlaxoSmithKline’s rheumatoid arthritis prospect misses phase 2 endpoint

GlaxoSmithKline’s rheumatoid arthritis prospect misses phase 2 endpoint

Fierce Pharma

rheumatoid arthritis

clinical trials

Flag link:

Are all new sales created equal?

Are all new sales created equal?

EP Vantage

Flag link:

7 drugmakers to watch during Q3 earnings

7 drugmakers to watch during Q3 earnings

Biopharma Dive

Gilead Sciences

Flag link:

GlaxoSmithKline helps immunometabolism startup Sitryx to $30M round

GlaxoSmithKline helps immunometabolism startup Sitryx to $30M round

Fierce Biotech

immunometabolism

drug development

Flag link:

Pages